LEADERSHIP
38 ctful antibiotics currently in the pipeline . Beyond this , the company is brainstorming with GARDP and is looking at ways to increase paediatric development for deadly diseases such as sepsis . Most importantly , the partnership focuses on sharing knowledge , information and gaining insights on improving generic antibiotic formulations for children .
Although paediatric clinical trials remain limited , presenting significant challenges , NSB ’ s adaptive R & D approach within Sandoz has allowed the business to anticipate demand and gain a further understanding of where to add supplies and develop further applications .
“ We have a certain strength in Sandoz to develop new formulations . For example , we underwent a specific development of Amoxicillin as a dispersible tablet with interest from UNICEF .
DECEMBER 2018